Clinique de Sclérose en plaques du Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada/Department of Neurosciences, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada/Département de Neurologie, CRC sclérose en plaques, CHU Montpellier, INSERM, Université Montpellier, Montpellier, France.
Clinique de Sclérose en plaques du Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada/Department of Neurosciences, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Mult Scler. 2021 Apr;27(4):613-620. doi: 10.1177/1352458520923945. Epub 2020 May 27.
Recent progress in multiple sclerosis (MS) management has contributed to a greater life expectancy in persons with MS. Ageing with MS comes with unique challenges and bears the potential to greatly affect quality of life and socioeconomic burden.
To compare frailty in ageing persons with multiple sclerosis (pwMS) and controls; to correlate frailty with MS clinical characteristics.
PwMS and controls over 50 years old were recruited in a cross-sectional study. Two validated frailty measures were assessed: the frailty index and the Fried's phenotype. Several multiple linear regressions accounting for demographic and clinical characteristics were performed.
Eighty pwMS (57 females, mean age 58.5 ± 6 years old) and 37 controls (24 females, mean age 61 ± 6.5 years old) were recruited. Multivariable analysis identified significantly higher frailty index in pwMS (0.21 ± 0.12 vs 0.11 ± 0.08, p < 0.0001). Similarly, according to Fried's phenotype, a significantly higher percentage of pwMS were frail compared to controls (28% vs 8%). In pwMS, frailty index was independently associated with expanded disability status scale (EDSS), comorbidities, education level and disease duration.
Our results suggest that frailty can be routinely assessed in pwMS. Increased frailty in MS patients suggests that, along with MS therapeutics, a tailored multidisciplinary approach of ageing pwMS is needed.
多发性硬化症（MS）管理的最新进展使 MS 患者的预期寿命延长。随着年龄的增长，MS 患者会面临独特的挑战，并有可能极大地影响生活质量和社会经济负担。
比较多发性硬化症（pwMS）老年患者与对照组的衰弱情况；将衰弱与 MS 临床特征相关联。
在一项横断面研究中，招募了 50 岁以上的 pwMS 和对照组。评估了两种经过验证的衰弱测量方法：衰弱指数和弗里德表型。进行了多项多元线性回归分析，考虑了人口统计学和临床特征。
共招募了 80 名 pwMS（57 名女性，平均年龄 58.5±6 岁）和 37 名对照组（24 名女性，平均年龄 61±6.5 岁）。多变量分析发现 pwMS 的衰弱指数明显更高（0.21±0.12 比 0.11±0.08，p<0.0001）。同样，根据弗里德表型，与对照组相比，pwMS 中虚弱的比例明显更高（28%比 8%）。在 pwMS 中，衰弱指数与扩展残疾状况量表（EDSS）、合并症、教育水平和疾病持续时间独立相关。
我们的研究结果表明，衰弱可以在 pwMS 中常规评估。MS 患者的衰弱程度增加表明，除了 MS 治疗外，还需要针对 pwMS 老龄化的量身定制的多学科方法。
